» Articles » PMID: 37684586

Computational Biology and in Vitro Studies for Anticipating Cancer-related Molecular Targets of Sweet Wormwood (Artemisia Annua)

Overview
Publisher Biomed Central
Date 2023 Sep 8
PMID 37684586
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cancer is one of the leading causes of death worldwide. Recently, it was shown that many natural extracts have positive effects against cancer, compared with chemotherapy or recent hormonal treatments. A. annua is an annual medicinal herb used in the traditional Chinese medicine. It has also been shown to inhibit the proliferation of various cancer cell lines.

Methods: Multi-level modes of action of A. annua constituents in cancer therapy were investigated using an integrated approach of network pharmacology, molecular docking, dynamic simulations and in-vitro cytotoxicity testing on both healthy and cancer cells.

Results: Network pharmacology-based analysis showed that the hit Artemisia annua constituents related to cancer targets were 3-(2-methylpropanoyl)-4-cadinene-3,11-diol, artemisinin G, O-(2-propenal) coniferaldehyde, (2-glyceryl)-O-coniferaldehyde and arteamisinin III, whereas the main cancer allied targets were NFKB1, MAP2K1 and AR. Sixty-eight significant signaling KEGG pathways with p < 0.01 were recognized, the most enriched of which were prostate cancer, breast cancer, melanoma and pancreatic cancer. Thirty-five biological processes were mainly regulated by cancer, involving cellular response to mechanical stimulus, positive regulation of gene expression and transcription. Molecular docking analysis of the top hit compounds against the most enriched target proteins showed that 3-(2-methylpropanoyl)-4-cadinene-3,11-diol and O-(2-propenal) coniferaldehyde exhibited the most stabilized interactions. Molecular dynamics simulations were performed to explain the stability of these two compounds in their protein-ligand complexes. Finally, confirmation of the potential anticancer activity was attained by in-vitro cytotoxicity testing of the extract on human prostate (PC-3), breast (MDA-MB-231), pancreatic (PANC-1) and melanoma (A375) cancerous cell lines.

Conclusion: This study presents deeper insights into A. annua molecular mechanisms of action in cancer for the first time using an integrated approaches verifying the herb's value.

Citing Articles

Exploring the therapeutic potential of marjoram (Origanum majorana L.) in polycystic ovary syndrome: insights from serum metabolomics, network pharmacology and experimental validation.

Elfiky A, Ibrahim R, Khattab A, Kadry M, Ammar N, Shawky E BMC Complement Med Ther. 2025; 25(1):67.

PMID: 39984989 PMC: 11846456. DOI: 10.1186/s12906-025-04774-5.

References
1.
Ibrahim R, Mahrous R, Abu El-Khair R, Ross S, Omar A, Fathy H . Biologically guided isolation and ADMET profile of new factor Xa inhibitors from roots using and approaches. RSC Adv. 2022; 11(17):9995-10001. PMC: 8695410. DOI: 10.1039/d1ra00359c. View

2.
Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

3.
Li D, Wu C, Cai Y, Liu B . Association of NFKB1 and NFKBIA gene polymorphisms with susceptibility of gastric cancer. Tumour Biol. 2017; 39(7):1010428317717107. DOI: 10.1177/1010428317717107. View

4.
Tabti K, Ahmad I, Zafar I, Sbai A, Maghat H, Bouachrine M . Profiling the structural determinants of pyrrolidine derivative as gelatinases (MMP-2 and MMP-9) inhibitors using in silico approaches. Comput Biol Chem. 2023; 104:107855. DOI: 10.1016/j.compbiolchem.2023.107855. View

5.
Konstat-Korzenny E, Ascencio-Aragon J, Niezen-Lugo S, Vazquez-Lopez R . Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer. Med Sci (Basel). 2018; 6(1). PMC: 5872176. DOI: 10.3390/medsci6010019. View